Expression of multiple unique rejection antigens on murine leukemia BALB/c RL ♂ 1 and the role of dominant Akt antigen for tumor escape

Journal of Immunology

Volumn 162, Issue 11, 1999, Pages 6420-6425

  Matsuo, Mitsutoshi ^a,b   Wada, Hisashi ^a   Honda, Shinichiro ^a   Tawara, Isao ^a   Uenaka, Akiko ^a   Kanematsu, Takashi ^b   Nakayama, Eiichi ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR ANTIGEN;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; HELPER CELL; IMMUNOGENICITY; IMMUNOREGULATION; LYMPHOCYTE CLONE; MOUSE; MURINE LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TUMOR CELL LINE; TUMOR ESCAPE;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NEOPLASM; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLONE CELLS; CROSSES, GENETIC; CYTOTOXICITY TESTS, IMMUNOLOGIC; FEMALE; GENES, DOMINANT; GRAFT REJECTION; INJECTIONS, INTRADERMAL; LEUKEMIA, EXPERIMENTAL; LEUKEMIA, RADIATION-INDUCED; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED DBA; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; PEPTIDES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; TUMOR ESCAPE;

EID: 0033152689     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Gross, L. 1943. Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res. 3:326.
2. Foley, E. L. 1953. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res. 13:835.
3. Prehn, R. T., and J. M. Main. 1957. Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. 18:769.
4. Klein, G., H. O. Sjögren, E. Klein, and K. E. Hellström. 1960. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res. 20:1561.
5. Globerson, A., and M. Feldman. 1964. Antigenic specificity of benzo(a)pyrene-induced sarcomas. J. Natl. Cancer Inst. 32:1229.
6. Van den Eynde, B., and P. van der Bruggen. 1997. T cell-defined tumor antigens. Curr. Opin. Immunol. 9:684.
7. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281.
8. Robbins, P. F., M. El-Gamil, Y. F. Li, Y. Kawakami, D. Loftus, E. Appella, and S. A. Rosenberg. 1996. A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor-infiltrating lymphocytes. J. Exp. Med. 183:1185.
9. Rubinfeld, B., P. Robbins, M. El-Gamil, I. Albert, E. Porfiri, and P. Polakis. 1997. Stabilization of β-catenin by genetic defects in melanoma cell lines. Science 275:1790.
10. Mandruzzato, S., F. Brasseur, G. Andry, T. Boon, and P. van der Bruggen. 1997. A CASP-8 mutation recognized by cylolylic T lymphocytes on a human head and neck carcinoma. J. Exp. Med. 186:785.
11. Sato, H., E. A. Boyse, T. Aoki, C. Iritani, and L. J. Old. 1973. Leukemia-associated transplantation antigens related to murine leukemia virus. The X.I system: immune response controlled by a locus linked to H-2. J. Exp. Med. 138:593.
12. Nakayama, E., H. Shiku, T. Takahashi, H. F. Oettgen, and L. J. Old. 1979. Definition of a unique cell surface antigen of mouse leukemia RL♂1 by cell-mediated cytotoxicity. Proc. Natl. Acad. Sci. USA 76:3486.
13. Uenaka, A., T. Ono, T. Akisawa, H. Wada, T. Yasuda, and E. Nakayama. 1994. Identification of a unique antigen peptide pRL1 on BALB/c RL♂1 leukemia recognized by cytotoxic T lymphocytes and its relation to the akt oncogene. J. Exp. Med. 180:1599.
14. Wada, H., M. Matsuo, A. Uenaka, N. Shimbara, K. Shimizu, and E. Nakayama. 1995. Rejection antigen peptides on BALB/c RL♂1 leukemia recognized by cytotoxic T lymphocytes: derivation from the normally untranslated 5′ region of the c-akt proto-oncogene activated by long terminal repeat. Cancer Res. 55:4780.
15. Stockert, E., A. B. DeLeo, P. V. O'Donnell, Y. Obata, and L. J. Old. 1979. G(AKSL2): a new cell surface antigen of the mouse related to the dualtropic mink cell focus-inducing class of murine leukemia virus detected by naturally occurring antibody. J. Exp. Med. 149:200.
16. DeLeo, A. B., H. Shiku, T. Takahashi, M. John, and L. J. Old. 1977. Cell surface antigens of chemically induced sarcomas of the mouse: murine leukemia virus-related antigens and alloantigens on cultured fibroblasts and sarcoma cells: description of a unique antigen on BALB/c Meth A sarcoma. J. Exp. Med. 146:720.
17. Dunn, T. B., and M. Potter. 1957. A transplantable mast-cell neoplasm in the mouse. J. Natl. Cancer Inst. 18:587.
18. - antigen with a cytolytic T cell stimulation assay. Immunogenetics 26:178.
19. Dialynas, D. P., Z. S. Quan, K. A. Wall, A. Pierres, J. Quintans, M. R. Loken, M. Pierres, and F. W. Fitch. 1983. Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. J. Immunol. 131:2445.
20. Kubo, R. T., W. Born, J. W. Kappler, P. Marrack, and M. Pigeon. 1989. Characterization of a monoclonal antibody which detects all murine αβ T cell receptors. J. Immunol. 142:2736.
21. d antigen, the products of a third polymorphic locus of the mouse MHC. J. Immunol. 125:2473.
22. Bellacosa, A., T. F. Franke, M. E. Gonzalez-Portal, K. Datta, T. Taguchi, J. Gardner, J. Q. Cheng, J. R. Testa, and P. N. Tsichlis. 1993. Structure, expression, and chromosomal mapping of c-akt: relationship to v-akt and its implications. Oncogene 8:745.
23. Wortzel, R. D., C. Phillips, and H. Schreiber. 1983. Multiple tumour-specific antigens expressed on a single tumour cell. Nature 304:165.
24. Uyttenhove, C., J. L. Maryanski, and T. Boon. 1983. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J. Exp. Med. 157:1040.
25. Dudley, M. E., and D. C. Roopenian. 1996. Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens. J. Exp. Med. 184: 441.
26. Knuth, A., T. Wölfel, E. Klehmann, T. Boon, and K.-H. Meyer zum Büschenfelde. 1989. Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proc. Natl. Acad. Sci. USA 86:2804.
27. Van den Eynde, B., P. Hainaut, M. Hérin, A. Knuth, C. Lemoine, P. Weynants, P. van der Bruggen, R. Fauchet, and T. Boon. 1989. Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int. J. Cancer. 44: 634.
28. Ioannides, C. G., R. S. Freedman, C. D. Platsoucas, S. Rashed, and Y. P. Kim. 1991. Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. J. Immunol. 146:1700.
29. Urban, J. L., R. C. Burton, J. M. Holland, M. L. Kripke, and H. Schreiber. 1982. Mechanisms of syngeneic tumor rejection: susceptibility of host-selected progressor variants to various immunological effector cells. J. Exp. Med. 155:557.
30. Wortzel, R. D., J. L. Urban, and H. Schreiber. 1984. Malignant growth in the normal host after variant selection in vitro with cytolytic T-cell lines. Proc. Natl. Acad. Sci. USA 81:2186.
31. + T cells in recovery from antigen-induced autoimmune disease. J. Exp. Med. 178:909.
32. + β islet cell-reactive T cell clones that suppress autoimmune diabetes in nonobese diabetic mice. J. Exp. Med. 182:87.
33. + cells recognizing epitopes of the T cell receptor β-chain from a myelin basic protein-specific T cell clone. Eur. J. Immunol. 23:530.
34. Chou, Y. K., W. J. Morrison, A. D. Weinberg, R. Dedrick, R. Whitham, D. N. Bourdette, G. Hashim, H. Offner, and A. A. Vandenbark. 1994. Immunity to TCR peptides in multiple sclerosis: T cell recognition of Vβ 5.2 and Vβ 6.1 CDR2 peptides. J. Immunol. 152:2520.
35. North, R. J. 1986. Radiation-induced, immunologically mediated regression of an established tumor as an example of successful therapeutic immunomanipulation: preferential elimination of suppressor T cells allows sustained production of effector T cells. J. Exp. Med. 164:1652.
36. + T cell-mediated immunity. J. Exp. Med. 168:2193.
37. Mullen, C. A., J. L. Urban, C. Van Waes, D. A. Rowley, and H. Schreiber. 1985. Multiple cancers: tumor burden permits the outgrowth of other cancers. J. Exp. Med 162:1665.
38. + T suppressor cells in mice rendered unresponsive to tumor antigens by intravenous injection of irradiated tumor cells. Int. J. Cancer. 55:338.